Division of Nephrology

Michael Walsh

Associate Professor, Division of Nephrology, Department of Medicine

 

 

 

 

 

Education

Dr. Michael Walsh completed his medical degree, internal medicine residency, and nephrology fellowship all at the University of Calgary. He then pursued a Master's degree in clinical epidemiology with a focus on clinical trial methodology and an advanced fellowship in vasculitis and lupus nephritis at the University of Cambridge. He is also pursuing a PhD in Health Research Methodology

Research Interests

Dr. Michael Walsh's research interests include:

  1. the epidemiology of acute kidney injury, particularly in the perioperative setting
  2. the epidemiology of acute glomerulonephritis
  3. clinical trials in both acute kidney injury and acute glomerulonephritis
  4. clinical trial methodology
He is a member of the European Vasculitis Research Group EUVAS and the Population Health Research Institute. Dr. Walsh's research is funded by the Canadian Institutes of Health Research, National Institute of Health Research, Food and Drug Administration, National Health and Medical Research Council, and the Canadian Centre and Network for Trials Internationally. He is the co-principal investigator of the PEXIVAS trial and the Remote IMPACT trial and leads a large prospective cohort study in perioperative acute kidney injury.

 

Selected Publications

  1. Molnar A, Coca S, Devereaux P, Jain A, Kichulu A, Luo J, Parikh C, Paterson J, Siddiqui N, Wald R, Walsh M, Garg A. Statin use is associated with less acute kidney injury after major elective surgery. Journal of the American Society of Nephrology. Accepted. 2010
  2. Walsh M, Catapano F, Szpirt W, Bruchfeld A, Guillevin L, Haubitz M, Merkel P, Peh C, Pusey C, Jayne D. Plasma exchange in rapidly progressive glomerulonephritis and ANCA associated vasculitis: a meta-analysis. American Journal of Kidney Diseases. Epub ahead of print. 2011
  3. Hiemstra T and Walsh M, Mahr A, Savage CO, deGroot K, Harper L, Hauser T, Neumann I, Tesar V, Rissing KM, Pagnoux C, Schmitt W, Jayne DRW. Mycophenolate mofetil versus azathioprine for remission maintenance in ANCA-associated vasculitis: a randomized control trial. Journal of the American Medical Association. 304(21):2381-2388.2010. (Joint first authorship).
  4. Jones R, Cohen Tevaert JW, Hauser T, Luqmani R, Morgan M, Peh C, Savage CO, Segelmark M, Tesar V, van Passen P, Walsh D, Walsh M, Westman K, Jayne D. Randomised trial of rituximab versus cyclophosphamide in ANCA associated renal vasculitis. New England Journal of Medicine. 363: 211-220. 2010.
  5. Walsh M, Merkel P, Mahr A, Jayne DRW. A systematic review and meta-analysis of relapses in anti-neutrophil cytoplasm antibody associated vasculitis: the effect of glucocorticoids. Arthritis Care and Research. 2010.
  6. Walsh M, Sar A, Benediktsson H, Manns B, Yilmaz S, Hemmelgam B. Histopathologic features in predicting risk of progression of IgA nephropathy. Clinical Journal of the American Society of Nephrology. 5: 425-430. 2010.
  7. Walsh M, Jayne D, Tonelli M, Moist L, Pannu N, Manns B. Practice pattern variation in glucocorticoid use in proliferative lupus nephritis. Lupus. 19:628-633.2010.
  8. Walsh M, Chauhdry A, Jayne D. Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody Alemtuzumab (CAMPATH-1H). Annals of the Rheumatic Diseases. 67:1322-1327. 2008.
  9. Culleton B, Walsh M, Klarenbach S, Mortis G, Scott-Douglas N, Quinn R, Tonelli M, Donnelly S, Friedrich M, Kumar A, Mahallati H, Hemmelgarn B, Manns B. The impact of nocturnal hemodialysis and conventional hemodialysis on left ventricular mass and quality of life. Journal of the American Medical Association. 298:1291-1299. 2007